[Skip to Navigation]
Sign In
Comment & Response
March 3, 2022

Cabozantinib for Treatment of Brain Metastases in Patients With Renal Cell Carcinoma

Author Affiliations
  • 1Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China
  • 2State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China
  • 3China Pituitary Disease Registry Center, Chinese Pituitary Adenoma Cooperative Group, Beijing, PR China
  • 4China Alliance of Rare Diseases, Beijing, PR China
JAMA Oncol. 2022;8(5):783. doi:10.1001/jamaoncol.2022.0052

To the Editor In their cohort study in JAMA Oncology, Hirsch et al1 found that cabozantinib had considerable intracranial activity and an acceptable safety profile in patients with renal cell carcinoma with brain metastases. These findings substantiate the superiority of cabozantinib for treatment of renal cell carcinoma with brain metastases. However, the conclusions should be critically interpreted and require more suggestions.

Add or change institution
×